Autoinflammatory Disease Mechanisms and Therapeutic Strategies

Autoinflammatory diseases arise from dysregulation of the innate immune system, in which genetic or acquired factors lead to aberrant activation of pattern‐recognition receptors and intracellular signalling complexes. Central to many syndromes is the formation of inflammasomes—multiprotein platforms that activate caspase-1 and drive release of interleukin-1β and interleukin-18. Monogenic variants affecting components such as NLRP3, NLRC4 or pyrin often confer gain-of-function properties, causing spontaneous or stimulus-independent inflammasome assembly, pyroptotic cell death and systemic inflammation. In parallel, dysregulated production of haematopoietic growth factors, including granulocyte colony-stimulating factor, can amplify myeloid cell expansion and sustain chronic tissue damage. Therapeutic strategies have accordingly focused on cytokine blockade, small-molecule inhibitors of inflammasome components and, in severe inherited cases, haematopoietic stem cell transplantation. Targeting upstream signalling pathways, fine-tuning metabolic checkpoints in myeloid cells and employing precision medicine approaches to match inhibitor sensitivity to mutation profiles are emerging as means to improve disease control while minimising immunosuppression.

Research from Nature Portfolio

Recent studies have shown that a specific autoinflammatory syndrome driven by gain-of-function mutations in a phospholipase Cγ2 variant is critically dependent on excessive granulocyte colony-stimulating factor. In a murine model carrying the human mutation, neutralising antibodies against granulocyte colony-stimulating factor reversed established disease, normalised myelopoiesis and restored lymphocyte counts, demonstrating that targeted cytokine depletion can cure a genetically defined condition. Separate investigations into cryopyrin-associated periodic syndromes have revealed that certain NLRP3 mutations assemble into constitutively active inflammasomes without external priming. These preactivated complexes induce basal pyroptosis and interleukin-18 secretion, yet are amenable to selective NLRP3 inhibitors and regulated by deubiquitination. Intriguingly, chronic activation alters cellular metabolism—limiting glycolysis and lipid pathways—and thereby restrains interleukin-1β output, suggesting that modulation of immunometabolic circuits could refine inflammasome-targeted therapies.

Autoinflammatory Disease Mechanisms and Therapeutic Strategies publication trend

The graph below shows the total number of articles in autoinflammatory disease mechanisms and therapeutic strategies across all publications each year (not limited to Nature Index journals).

Technical terms

Autoinflammatory disease: A disorder characterised by unprovoked innate immune activation without high‐titer autoantibodies or antigen‐specific T cells.

Inflammasome: A cytosolic multiprotein complex that activates caspase-1, triggering cytokine maturation and pyroptosis.

NLRP3: A pattern‐recognition receptor that forms part of an inflammasome, sensing microbial or danger signals.

Pyroptosis: A form of programmed cell death mediated by gasdermin D that releases inflammatory mediators.

Cytokine: A secreted protein that modulates immune cell communication and function.

Granulocyte colony-stimulating factor (G-CSF): A haematopoietic growth factor that promotes proliferation and differentiation of neutrophil precursors.

References

1. G-CSF drives autoinflammation in APLAID. Nature Immunology (2023).
2. Pathogenic NLRP3 mutants form constitutively active inflammasomes resulting in immune-metabolic limitation of IL-1β production. Nature Communications (2024).
3. Functional diversity of NLRP3 gain-of-function mutants associated with CAPS autoinflammation. Journal of Experimental Medicine (2024).
4. Targeting the NLRP3 inflammasome in cochlear macrophages protects against hearing loss in chronic suppurative otitis media. Journal of Neuroinflammation (2024).
5. Anakinra Therapy for Non-cancer Inflammatory Diseases. Frontiers in Pharmacology (2018).